The survival benefits of local surgery in stage IV breast cancer are not affected by breast cancer subtypes: a population-based analysis
- PMID: 28978078
- PMCID: PMC5620218
- DOI: 10.18632/oncotarget.18889
The survival benefits of local surgery in stage IV breast cancer are not affected by breast cancer subtypes: a population-based analysis
Abstract
This retrospective study aimed to investigate the clinical value of local surgery in stage IV BC and determined whether the survival outcomes were affected by the breast cancer subtype (BCS). Women with de novo stage IV BC from 2010 to 2013 were included using the Surveillance Epidemiology and End Results database. Univariate and multivariate Cox regression analyses were performed to evaluate the prognostic factors for breast cancer-specific survival (BCSS) and overall survival (OS). Among 9,256 patients were identified, 3,130 (33.8%) were received local surgery. Patients with hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- subtype were less likely to receive local surgery, while HR-/HER2- tumors were more likely to receive surgery. Multivariate analyses revealed that local surgery improved survival, surgical intervention was an independent favorable prognostic factor for BCSS (P < 0.001) and OS (P < 0.001). Patients who receipt of surgery had better survival outcomes compared with the non-surgery group, and the survival benefits of local surgery were not affected by the BCS status. Local surgery was improved survival for patients with stage IV BC regardless of the BCS status.
Keywords: SEER program; breast cancer; subtype; surgery; survival.
Conflict of interest statement
CONFLICTS OF INTEREST No any actual or potential conflicts of interest exist.
Figures


Similar articles
-
Metastatic Pattern Discriminates Survival Benefit of Type of Surgery in Patients With De Novo Stage IV Breast Cancer Based on SEER Database.Front Surg. 2021 Nov 3;8:696628. doi: 10.3389/fsurg.2021.696628. eCollection 2021. Front Surg. 2021. PMID: 34805256 Free PMC article.
-
The association between molecular type and prognosis of patients with stage IV breast cancer: an observational study based on SEER database.Gland Surg. 2021 Jun;10(6):1889-1898. doi: 10.21037/gs-21-32. Gland Surg. 2021. PMID: 34268073 Free PMC article.
-
Nomogram Predicts the Role of Primary Tumor Surgery on De Novo Stage-IV Breast Cancer Patients: A SEER-Based Competing Risk Analysis Model.Front Oncol. 2022 May 4;12:819531. doi: 10.3389/fonc.2022.819531. eCollection 2022. Front Oncol. 2022. PMID: 35600374 Free PMC article.
-
Prognostic role of radiotherapy in low-risk elderly breast cancer patients after breast-conserving surgery: a cohort study.Gland Surg. 2022 May;11(5):847-859. doi: 10.21037/gs-22-235. Gland Surg. 2022. PMID: 35694094 Free PMC article.
-
A retrospective comparative cohort study of SEER database analysis of the prognostic value of breast-conserving surgery and mastectomy in patients with multifocal multicenter breast cancer.Gland Surg. 2023 Feb 28;12(2):165-182. doi: 10.21037/gs-22-682. Epub 2023 Feb 27. Gland Surg. 2023. PMID: 36915807 Free PMC article.
Cited by
-
Patterns of de novo metastasis and survival outcomes by age in breast cancer patients: a SEER population-based study.Front Endocrinol (Lausanne). 2023 Nov 6;14:1184895. doi: 10.3389/fendo.2023.1184895. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38027167 Free PMC article.
-
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.Breast Cancer Res Treat. 2024 Jan;203(2):351-363. doi: 10.1007/s10549-023-07116-6. Epub 2023 Oct 25. Breast Cancer Res Treat. 2024. PMID: 37878152
-
Outcomes following stereotactic radiosurgery or whole brain radiation therapy by molecular subtype of metastatic breast cancer.Rep Pract Oncol Radiother. 2021 Jun 9;26(3):341-351. doi: 10.5603/RPOR.a2021.0045. eCollection 2021. Rep Pract Oncol Radiother. 2021. PMID: 34277087 Free PMC article.
-
Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis.Sci Rep. 2020 Feb 19;10(1):2952. doi: 10.1038/s41598-020-59908-1. Sci Rep. 2020. PMID: 32076063 Free PMC article.
-
Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review.Cancer Manag Res. 2021 Aug 20;13:6537-6566. doi: 10.2147/CMAR.S300869. eCollection 2021. Cancer Manag Res. 2021. PMID: 34447271 Free PMC article. Review.
References
-
- Cancer Research UK Worldwide cancer statistics. Cancer Res UK. 2014
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
-
- Zheng R, Zeng H, Zhang S, Chen T, Chen W. National estimates of cancer prevalence in China, 2011. Cancer Lett. 2016;370:33–38. - PubMed
-
- DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66:31–42. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous